Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta

Trial Profile

Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Osteogenesis imperfecta
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 20 Jan 2017 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021.
    • 20 Jan 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2019.
    • 26 Aug 2016 This trial was completed in Czech Republic (end date: 2015-10-22), according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top